EcoDrugPlus

Bradykinin Receptor B2

Ensembl ID : ENSPREG00000005021
Gene Symbol: BDKRB2
1 Cross references
244 Possible Orthologues:

Bradykinin Receptor B2

Ensembl ID : ENSPREG00000005003
Gene Symbol: BDKRB2
1 Cross references
244 Possible Orthologues:

Bradykinin Receptor B2

Ensembl ID : ENSPREG00000004994
Gene Symbol: BDKRB2
4 Cross references
161 Possible Orthologues:

Camp-Specific 3',5'-Cyclic Phosphodiesterase 4b-Like

Ensembl ID : ENSPREG00000005074
Gene Symbol: LOC103479018
2 Cross references
224 Possible Orthologues:

Camp-Specific 3',5'-Cyclic Phosphodiesterase 4c-Like

Ensembl ID : ENSPREG00000000139
Gene Symbol: LOC103456889
3 Cross references
193 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Gamma Subunit 7a

Ensembl ID : ENSPREG00000000897
Gene Symbol: CACNG7A
2 Cross references
184 Possible Orthologues:

Calcium Sensing Receptor

Ensembl ID : ENSPREG00000020592
Gene Symbol: CASR
3 Cross references
202 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Alpha2delta 1

Ensembl ID : ENSPREG00000014119
Gene Symbol: CACNA2D1
4 Cross references
226 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Alpha2delta 2

Ensembl ID : ENSPREG00000004538
Gene Symbol: CACNA2D2
3 Cross references
209 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Alpha2delta 2

Ensembl ID : ENSPREG00000001246
Gene Symbol: CACNA2D2
3 Cross references
195 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Alpha2delta 3

Ensembl ID : ENSPREG00000019091
Gene Symbol: CACNA2D3
4 Cross references
210 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Alpha2delta 4

Ensembl ID : ENSPREG00000004295
Gene Symbol: CACNA2D4
2 Cross references
233 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).